To compare the drugs Ropivacaine and Dexmedetomidine nebulization in preventing sore throat after surgeries.

A comparative study of nebulised ropivacaine and dexmedetomidine in the prevention of postoperative sore throat following general anaesthesia : A prospective study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/096565

Enrollment

Registered

2025-10-29

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Nebulization with Dexmedetomidine 50 mcg (0.5 mL) with 4.5 mL normal saline will be given to group D and nebulization Ropivacaine 0.75% 5 mL in group R.: Nebulization will be given in

Eligibility

Inclusion criteria

Inclusion criteria: Patients willing to give consent American Society of Anaesthesiology physical status I and II Age between 18 to 60 years Airway assessment by Mallampati grade I and II Patients undergoing elective surgeries under general anaesthesia with endotracheal intubation

Exclusion criteria

Exclusion criteria: Duration of surgery is more than 3 hrs Cardiopulmonary comorbidities Patients receiving corticosteroids Pre-existing pharyngeal laryngeal disease and sore throat

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of nebulised Ropivacaine and nebulised Dexmedetomidine in preventing postoperative sore throat following intubation in patients undergoing general anaesthesia. To compare the efficacy of nebulised ropivacaine and nebulised dexmedetomidine on the haemodynamic response before and after intubation. To compare incidence of side effects of nebulised ropivacaine and nebulised dexmedetomidine postoperatively in patients undergoing general anaesthesia.Timepoint: Postoperative sore throat will be assessed at 1,2,4,6,12 and 24 hours after surgery. Haemodynamic data will be assessed before nebulisation, after nebulisation, before tracheal intubation, after intubation, 5 minutes after intubation, at closure of skin incision, immediately after extubation, 5 minutes after extubation. All adverse events occurring during the postoperative period related to the use of nebulised ropivacaine and dexmedetomidine will be assessed for the next 24 hours.	—

Measure

Time frame

To compare the efficacy of nebulised Ropivacaine and nebulised Dexmedetomidine in preventing postoperative sore throat following intubation in patients undergoing general anaesthesia. To compare the efficacy of nebulised ropivacaine and nebulised dexmedetomidine on the haemodynamic response before and after intubation. To compare incidence of side effects of nebulised ropivacaine and nebulised dexmedetomidine postoperatively in patients undergoing general anaesthesia.Timepoint: Postoperative sore throat will be assessed at 1,2,4,6,12 and 24 hours after surgery. Haemodynamic data will be assessed before nebulisation, after nebulisation, before tracheal intubation, after intubation, 5 minutes after intubation, at closure of skin incision, immediately after extubation, 5 minutes after extubation. All adverse events occurring during the postoperative period related to the use of nebulised ropivacaine and dexmedetomidine will be assessed for the next 24 hours.

—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactVinod Basappa Hosalli

Sapthagiri Institute of Medical Sciences and Research Centre

vinodhosallidr@gmail.com8310268837

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026